Cribriform plate CSF egress failure drives Alzheimer's pathology
PrimaryLeucadia's central causal theory is that age-related or pathological narrowing of CSF egress pathways through the cribriform plate reduces cerebrospinal-fluid-mediated clearance from upstream brain regions, especially medial temporal lobe and basal forebrain areas relevant to memory. Reduced clearance is proposed to allow toxic macromolecules, including amyloid-beta, to accumulate and contribute to Alzheimer's disease pathology and cognitive decline. Testable predictions include: cribriform plate aperture cross-sectional area and modeled CSF flux capacity should decline with age; people with Alzheimer's disease should have smaller CSF egress capacity than cognitively healthy controls; CT-derived cribriform plate morphology should correlate with memory and olfactory measures; and experimental occlusion of cribriform plate apertures should induce neurodegenerative and cognitive phenotypes.
Popperian evaluation
The premise is biologically credible: CSF and interstitial-fluid clearance are already tied to amyloid-beta handling, and the cribriform plate is a real anatomical exit route for CSF near olfactory structures. The harder claim is causal weight. The evidence supports narrowing and reduced modeled flux with age, but it does not yet prove that this route is large enough, early enough, and specific enough to drive Alzheimer's pathology by itself.
Supporting evidence: The theory identifies a concrete drainage path: CSF can move from subarachnoid spaces under the olfactory bulb through olfactory structures and cribriform plate conduits toward the nasal mucosa.; A 2024 CLIC editorial frames impaired ISF and CSF clearance as relevant to amyloid-beta elimination in aging, Alzheimer's disease, cerebral amyloid angiopathy, and retinal amyloid vasculopathy.; The medRxiv study reports that cribriform plate aperture cross-sectional area and modeled CSF flux capacity decline with increasing age.
Counter evidence: The central premise still depends on the assumption that cribriform plate egress capacity is causal rather than a marker of aging, skull morphology, olfactory damage, vascular disease, or broader neurodegeneration.; The supplied evidence does not quantify how much total brain clearance depends on this route compared with other CSF, glymphatic, perivascular, lymphatic, and vascular clearance pathways.; The main disease-specific evidence comes from one preprint-centered package rather than multiple independent cohorts.
The theory explains a coherent cluster: aging narrows a drainage route, Alzheimer's cases show lower modeled flux, olfactory and memory measures track cribriform morphology, and ferret occlusion produces temporal-lobe and olfactory damage. That is a serious pattern. It still has to beat simpler alternatives: cribriform changes may travel with age, inflammation, trauma, vascular pathology, or neurodegeneration rather than sit upstream of them.
Supporting evidence: Post-mortem subjects with confirmed Alzheimer's disease reportedly had the smallest modeled CSF flux capacity.; A clinical study of 560 participants linked CT-derived cribriform plate morphology with memory and olfactory assessment, and reported feasibility for predicting Alzheimer's disease before clinical cognitive impairment.; Adult ferrets with surgically occluded cribriform plate apertures reportedly developed progressive spatiotemporal memory deficits and atrophy of the temporal lobe, olfactory bulbs, and lateral olfactory stria.
Counter evidence: The human evidence is largely correlational, so it cannot yet separate cause from consequence.; Alzheimer's disease has strong competing explanatory layers, including amyloid processing, tau pathology, vascular injury, inflammation, sleep-linked clearance, and genetic risk.; The evidence does not show that restoring cribriform egress reduces amyloid-beta, tau pathology, or cognitive decline in humans.
This theory is highly testable. It names anatomy, measurable morphology, modeled flux, disease state, age effects, cognition, olfaction, and an animal perturbation. A clean negative result could hurt it badly: normal cribriform egress in well-phenotyped Alzheimer's cohorts, no longitudinal risk signal, or no pathology rescue after restoring flow would force a major revision.
Supporting evidence: It predicts that cribriform plate aperture cross-sectional area and modeled CSF flux capacity should decline with age.; It predicts that people with Alzheimer's disease should have smaller cribriform plate CSF egress capacity than cognitively healthy controls.; It predicts that CT-derived morphology should correlate with memory and olfactory measures.; It predicts that experimental occlusion of cribriform plate apertures should induce neurodegenerative and cognitive phenotypes.
Counter evidence: Some predictions rely on modeled CSF flux capacity rather than direct in vivo flux measurement, which gives the theory room to survive measurement disputes.; The theory would be stronger if it specified effect-size thresholds, timing relative to amyloid and tau accumulation, and what result would count as a decisive failure.
Reasoning tree
Public endorsements
Ethell publicly backs the theory. He is identified by Leucadia as founder, chairman, CEO, and the source of the research behind the company, and a 2018 talk tied to him describes Alzheimer’s as a "fixable plumbing problem," which matches the cribriform-plate CSF-egress hypothesis. A later event framing his work around reversing brain aging and Alzheimer’s with a tiny implantable device points the same way.
Evidence publication IDs: 679b73fd-a971-4b09-b074-b865c0ca286d
The public records here place Javed Siddiqi in Leucadia leadership, as director and chief medical officer, but they do not show any direct public statement from him about the cribriform-plate CSF egress theory. Board or leadership affiliation alone is not a public endorsement of that causal claim.